Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The Companyâ€™s wholly owned pipeline comprises five programs focused on the metabolic functions of the liver, muscle and blood. It offers AXA1665 for use in treating Hepatic Encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.